Form 4: KALA BIO Director C. Daniel Myers Receives Significant Equity Grants

KALA BIO, Inc. Director C. Daniel Myers was granted 2,450 restricted stock units and options to purchase 5,450 shares of common stock on June 15, 2025, as disclosed in a recent SEC Form 4 filing.

Summary

• C. Daniel Myers, a Director of KALA BIO, Inc. (KALA), acquired 2,450 shares of common stock in the form of Restricted Stock Units (RSUs) on June 15, 2025.
• These RSUs were granted under the Issuer's Amended and Restated 2017 Equity Incentive Plan at a price of $0 per share.
• The RSUs will vest 100% on the earlier of June 15, 2026, or the date of the first annual meeting of stockholders occurring in 2026, contingent on Mr. Myers' continued service.
• Following this transaction, C. Daniel Myers beneficially owns 10,374 shares of common stock, which includes 4,973 unvested RSUs.
• Additionally, Mr. Myers was granted stock options to purchase 5,450 shares of common stock on June 15, 2025, with an exercise price of $4.3 per share.
• These stock options also vest 100% on the earlier of June 15, 2026, or the date of the first annual meeting of stockholders occurring in 2026, contingent on continued service, and are set to expire on June 14, 2035.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of director compensation through equity grants. It's generally positive as it aligns interests but has no significant immediate impact on company operations or financial health beyond standard compensation practices.

Positives

• The equity grants align the interests of Director C. Daniel Myers with those of shareholders, incentivizing long-term performance and value creation.
• The grants serve as a retention mechanism for a key board member, ensuring continuity and commitment to the company's strategic objectives.

Negatives

• The issuance of new equity (RSUs and options) could lead to minor dilution for existing shareholders upon vesting and exercise, although the amount for a single director is typically not substantial.

Risks

• The vesting of both the Restricted Stock Units and stock options is contingent upon the reporting person's continued service to KALA BIO, Inc., meaning the benefits are not guaranteed if service ceases before the vesting dates.

Future Outlook

The granted Restricted Stock Units and stock options are set to vest 100% on the earlier of June 15, 2026, or the date of the first annual meeting of stockholders occurring in 2026, contingent on the director's continued service. The stock options have an expiration date of June 14, 2035.

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and pharmaceutical industries where equity grants, such as Restricted Stock Units and stock options, are commonly used to compensate and incentivize directors and executives. Such compensation structures aim to align the interests of leadership with long-term shareholder value creation, a prevalent strategy across publicly traded companies in the sector.

Comparison to Industry Standards

• Equity grants to directors are a common form of compensation in publicly traded companies, particularly in the biotech sector, aligning director interests with shareholder value.
• The vesting schedule (one year or next annual meeting) is typical for director equity grants, promoting retention and long-term commitment.
• The exercise price of $4.3 for the options is likely the fair market value on the grant date, which is standard practice for incentive stock options.

Related Party Transactions

• The grant of Restricted Stock Units and stock options to C. Daniel Myers, a Director of KALA BIO, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: Minor potential for dilution upon vesting and exercise of equity, but generally positive for aligning director incentives with shareholder value.
• Management: Strengthens alignment of director with company performance and long-term strategic goals.

Next Steps

• The granted Restricted Stock Units and stock options will vest on the earlier of June 15, 2026, or the date of the first annual meeting of stockholders occurring in 2026, subject to continued service.
• The stock options will remain exercisable until their expiration date of June 14, 2035.

Key Dates

Keywords

KALA BIO, KALA, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Incentive Plan, Director Compensation, C. Daniel Myers